Panagora Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Panagora Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-49,123	Closed	-$958K	–	1616
2022 Q1	$958K	Buy	49,123 +38,416	+359%	+$583K	0.01%	964
2021 Q4	$175K	Buy	+10,707	New	+$179K	﹤0.01%	1502
2018 Q2	–	Sell	-49,934	Closed	-$1.54M	–	2431
2018 Q1	$1.54M	Buy	+49,934	New	+$1.61M	0.01%	983
2017 Q3	–	Sell	-391	Closed	-$10K	–	2521
2017 Q2	$10K	Buy	+391	New	+$8.72K	﹤0.01%	2437
2015 Q3	–	Sell	-1,771	Closed	-$57K	–	2439
2015 Q2	$57K	Buy	+1,771	New	+$45.5K	﹤0.01%	2111
2014 Q3	–	Sell	-37,118	Closed	-$1.26M	–	2365
2014 Q2	$1.26M	Sell	37,118 -1,455	-4%	-$45.6K	0.01%	1014
2014 Q1	$1.22M	Buy	+38,573	New	+$1.21M	0.01%	1099

Other funds holding RVNC

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Panagora Asset Management's RVNC Position: Q2 2022 in Review

Panagora Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2022, closing a stake of 49,123 shares — an estimated $958K sold.

Panagora Asset Management first reported a position in RVNC in Q1 2014 and held it in 7 quarters. The position peaked at $1.54M in Q1 2018. 161 funds tracked by Wall St. Rank hold RVNC as of Q2 2022.

Panagora Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
Panagora Asset Management sold 49,123 Revance Therapeutics, Inc. shares in Q2 2022, an estimated $958K.
Panagora Asset Management first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 7 quarters.
Panagora Asset Management's Revance Therapeutics, Inc. position peaked at $1.54M in Q1 2018.
161 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2022.

Based on Panagora Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.